Buradasınız

Anasayfa » Content

FAMOTİDİN VE RANİTİDİNİN NON-ÜLSER DİSPEPSİLİ HASTALARDA İKİLİ ANTİBİYOTİK KOMBİNASYONU İLE BİRLİKTE KULLANILMASININ HP ERADİKASYONUNA ETKİLERİ ARASINDA FARK VAR MIDIR?

Are there any differences between ranitidin or famotidin plus dual antibiotic combination in patients with Helicobacter pylori positive nonulcer dyspepsia ?

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1999

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
H2 blockers have been used in gastric and duodenal ulcer and non-ulcer dyspepsia for years. Nowadays these drugs are used for maintenance therapy after Helicobacter pyolori (Hp) eradication. Aim of this study was to evaluate the efficacy and differences of ran t d n and famot d n plus dual ant b ot c therapy n Hp pos t ve non-ulcer dyspeps a patients. Hp positive patients with documented non-ulcer dyspepsia were randomised into two groups. First group was given amoxicillin 1gr bid, clarithromycin 500 mg bid for one week plus ranitidin 300 mg one a day for one month and second group was given amoxicillin 1 gr bid, clarithromycine 500 mg bid for one week plus famotidin 40 mg one a day for one month. Endoscopy with a biopsy was performed at enrollement and at 6 weeks. Hp infection was cured % 83,3 of those treated with ranitidin plus dual antibiotics (RAC) and in % 82.6 of those treated with famotidin plus dual antibiotics (FAC). Sypmptoms disappeared in % 87.5 of those treated with ranitidin plus dual antibiotics and in % 86.95 of those treated with famotidin and dual antibiotics. There were not any statistically significant differences between famotidin or ranitidin plus dual antibiotics combinations in patients with Hp positive non-ulcer dyspepsia.
Bookmark/Search this post with
Abstract (Original Language): 
Bilindiği gibi gastrik ülser, duodenal ülser ve non-ülser dispepsilerde H2 blokerler uzun yıllar kullanılmış, günümüzde de Helicobacter pylori (Hp) eradikasyonu sonrası idame tedavisinde tek başlarına ya da antasidlerle kombine olarak kullanılmaktadır. Biz bu çalışmamızda amoksisilin+klaritromisin kombinasyonuna ranitidin 300 mg veya famotidin 40 mg ekleyerek non-ülser dispepsilerde Hp eradikasyonundaki etkilerini araştırdık. Çalışmaya dispeptik yakınmalarla başvuran, endoskopilerinde ülser tesbit edilmeyen ve endoskopik biyopsilerinde Hp (+) bulunan gastrit yada bulbit tesbit edilen ve non-ülser dispepsi kabul edilen yaş ortalalaması 36.4 olan 47 hasta (31 erkek 16 kadın) alınarak hastalar rastgele iki guruba ayrıldı. Birinci gruptaki 24 hastaya bir hafta süre ile amoksisilin 2x1 gr + klaritromisin 2x500 mg'a ilave olarak dört hafta süre ile ranitidin 1x300 mg, ikinci gruptaki 23 hastaya ise bir hafta süre ile amoksisilin 2x1 gr + klaritromisin 2x500 mg + famotidin 40 mg 4 hafta süre ile uygulandı. Olguların endoskopileri başlangıçta ve altıncı haftada tekrarlandı. Birinci gruptaki 24 hastada Hp eradikasyon oranı %83.3 (20/24), ikinci gurptaki Hp eradikasyon oranı ise %82.6 (19/23) idi. Her iki gruptaki olgularda da gastrik histolojide düzelme izlendi. Sonuç olarak Hp pozitif non-ülser dispepsi olgularında ikili antibiyotikle hem ranitidin hem de famotidin kombinasyonu ile yüksek kür oranları elde edilmektedir. Aralarındaki fark istatistiksel olarak anlamlı değ ld
FULL TEXT (PDF): 
PDF icon arastirmax-famotidin-ranitidinin-non-ulser-dispepsili-hastalarda-ikili-antibiyotik-kombinasyonu-ile-birlikte-kullanilmasinin-hp-eradikasyonuna-etkileri-arasinda-fark-var-midir.pdf
  • 2
100-106
  • Turkish

REFERENCES

References: 

1.
Cindoru
k M, Akalın S, Doğan ÜB, Koşar Y, Yararyılmaz F, Çağatay M, Yıldırım S. Dispepsisi olan ve olmayan hastalarda Helicobacter pylori prevalansı ve Helicobacter pylori tansından kullanılan yöntemlerin karşılaştırılması. Turk J Gastroenterol 1996; 7:233-236.
2. Dooley CP, Fitzgibbons P, Cohen H, Appleman MD, Perez GP, Blazer MJ. Prevelance and distrubition of C.pylori in an asymptomatic population. Gastroenterology 1988; 945):A102.
3. Graham DY, Lew GM, Klein PD. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. Ann Intern Med 1992; 116: 705-8.
4. 4-NIH consensus development panel. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9.
5. Greaves RG, Cayla R, Mendelson MG, Lamouliatte H, Gummet PA, Baron JH, et al. Omeprazole versus clarithromycine for eradication of H. Pylori infection. Gastroenteology 1994; 106: A84.
6. Adamek RJ, Wegener M, Labenz J, Freitag M, Opferkuch W, Ruhl GH. Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. Am J Gastroenterol 1994; 89: 39-42.
7. Lamouliatte Herve. Adjuan Therapy for Helicobacter pylori eradication: Role of Lansoprazole in Clinical Studies. J Clin Gastroenterol 1995; 20 (Suppl. 1): s28-s31.
8. Ciociola AA, Webb DD, Turner K. Dual and triple therapy regimens of antisecretory agents and antibiotics for the eradication of Helicobacter pylor:i: An overview. Scand J Gastroenterol 1996; 31 suppl 218: 3-9.
9. Bayerdorffer E, Mannes GA, Sommer A, Höchter W, Weingart J, Hatz R, et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand J Gastroenterol 1993; 28 suppl 196: 19-25.
10. Ling TKW, Cheng AFB, Sung JJY, Yiu YLP, Chung SSC. An increase in Helicobacter pylori strains resistant to Metranidazole: A five year Study. Helicobacter 1996; 1(1):57-61.
11. Logan RPH, Bummett PA, Misiewicz JJ, Karim QN, Walker MM, Baron JH. One week eradication regimen for Helicobacter pylori. Lancet 1991;
338.1249-1252.
12. Hosking SW, Ling TKW, Yung MY, Cheng AFB, Chung SCS, Li AKC.
Randomized controlled trial of short term treatment to eradicate Helicobacter pyloir in patients with duodenal ulcer. Br Med J 1992;
305.502-504.
13. Bazolli F, Gullini S, Zagari R, Pazzi P, Dalla Libera M, Pozzato P, Sottil S, et al. Effect of omeprazole and clarithromycin plus tinidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer.
Gut 1995; 37: Suppl 1, A5.
14. Soil AH. Practice parameter Committee of the American College of Gastroenterology. Medical treatment of peptic ulcer disease. JAMA
1996; 275:622-9.
15. Labenz J, Ruhl GH, Stolte M, et al. Efficacy of one-week triple therapy to cure H.pylori infection (abstract 364). Am J Gastroenterol 1994;89 (Suppl): 1376.
16. Laine L, Estrada R, Trujillo M, Fukanaga K, Neil G. Randomized comparison of 7, 10 and 14 days of omeprazole, amoxycillin and clarithromycin for treatment of H.pylori (abstract 4510). In. Program and Abstracts of Digestive Diseases Week. San Francisco; 1996; A-
1128.
17. Riff DS, Kidd S, Rose P, Haber M, Weissfeld A, Siepman N. Triple therapy with lansoprazole, clarithromycin and amoxycillin forthe cure of Helicobacter pylori infection: A short report. Helicobacter 1996;1: 238¬42.
18. Mainguet P, Delmee M, Debongnie JC. Omeprazole, Campylobacter pylori and duodenal ulcer. Lancet 1989; 2: 389.
19. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35:490-
6.
20. Biasco G, Miglioli M, Barbara L, et al. Omeprazole, Helicobacter pylori gastritis and duodenal ulcer. Lancet 1989; 2. 1403.
21. Lamouliatte H, Bernard PH, Boulard A, et al. Omeprazole improves amoxicillin therapy directed towards Helicobacter pylori associated gastritis (abstract) Gastroenterol 1990; 88: A 75.
22. Labenz J, Gyenes E, Rühl GH, Börsch G. Amoxicillin/omeprazole cures ulcer disease associated with Helicobacter pylori infection. Am J Gastroenterol 1992; 87: 1270.
23. Van der Hulst Rene V.M, Keller JJ, Rauws EAJ, Tygat RG. Treatment of Helicobacter pylori infection: A Review of the World Literature. Helicobacter 1996; 1(1):6-20.
24. Rauws EAJ, Tygat GNJ. Eradication of Helicobacter pylori cures duodenal ulcer. Lancet 1990; i: 1233-5.
25. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on thelong-term recurrence of gastric or duodenal ulcer. A randomized controlled study. Ann Intern Med 1992;
116: 705-8.
26. Noach LA, Bertola MA, Schwartz MP, Rauws EAJ, Tygat GNJ. Treatment of Helicobacter pylori infection. An evaluation of various therapeutic trials. Eur J Gastroenterol Hepatol 1994; 6: 585-92.
27. Axon ATR. The role of omeprazole and antibiotic combination in the eradication of Helicobacter pylori: an update. Scand J Gastroenterol 1994; 29(Suppl 205): 31-7.
28. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol 1994; 29 Suppl 201):16-23.
29. Megraud F, Boyanova L, Lamouliatte H. Acitivity of Lansoprazole against Helicobacter pylori. Lancet 1991; 337: 1486.
30. Lahaie RG, Lemoyne M, Poitras P, et al. A randomized trail of the efficacy of three regimens for the eradication of Helicobacter pylori (abstract). Gastroenterology 1995; 108:141.
31. Lamouliatte H, Bernard PH, Cayla F, Megraud F, De Mascarel A, Quinton A. Controlled study of omeprazole-amoxicillin-tinidazole vs ranitidine-amoxicillin-tinidazole in Helicobacter pylori associated duodenal ulcer (DU). Final and long-term results (abstract). Gastroenterology 1992; 102:106.
32. AL Assi MT, Karttunen T, Genta RM, Graham DY. Which is important for omeprazole antimicrobial therapies: pH or antimicrobial activity? Comparison of amoxycillin and omeprazole and high dose ranitidine plus sodium bicarbonate. Am J Gastroenterol 1994; 89: 1362.
33.
Aydı
n A, Büker Ç, Akıner A, Kansu Z, Demir A, Günan C. Helicobacter pilorinin klaritromisine duyarlılığı azalıyor mu?. Ulusal Gastroenteroloji Haftası, XIV. Ulusal Gastroenteroloji Kongre Kitapcığı; Sayfa 55, 12-16
Eylül 1998, İstanbul.
34.
Kantarçeke
n B, Yıldırım B, Aladağ M, Karıncaoğlu M, Hilmioğlu F. Helicobacter pilori ve antibiyotik direnci. Ulusal Gastroenteroloji Haftası, XIV. Ulusal Gastroenteroloji Kongre Kitapcığı; Sayfa 1, 12-16 Eylül 1998, İstanbul.
35. Penston JG. Review article: Helicobacter pylori eradication-understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994 ; 8: 369-89.
36. Noach LA, Langenberg WL, Bertola MA, Dankert J, Tygat GNJ. Impact of metranidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 1994 ; 26:321-7.

Thank you for copying data from http://www.arastirmax.com